[
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "About",
    "section": "",
    "text": "About this site\n\n1 + 1\n\n[1] 2"
  },
  {
    "objectID": "tabs/resume/clinical_outcomes_intelligence.html",
    "href": "tabs/resume/clinical_outcomes_intelligence.html",
    "title": "Leveraging data intelligence to drive better clinical outcomes",
    "section": "",
    "text": "Operations\nThank you for this opportunity. I have a strong background in biostatistics and data science, which I believe aligns perfectly with the role’s needs. Over the years, I’ve developed not just technical expertise, but also a passion for contributing to positive health outcomes through data. For example, my work as a Senior Biostatistician at CAPRISA involved leading statistical planning for multiple clinical trials, ensuring we met both ethical and scientific standards while delivering meaningful results. In addition, I pride myself on my interpersonal skills, mentoring junior statisticians, and fostering collaboration across teams. I’m particularly excited about joining Mediclinic because of its focus on data-driven decision-making, and I’m confident that my experience in healthcare analytics will allow me to contribute to improving clinical outcomes in a meaningful way.\nKey Focus\n\nLong-term commitment to healthcare analytics.\nHighlight teamwork and mentorship experience.\nEmphasize alignment with Mediclinic’s focus on improving clinical performance.\n\nQuestions to Ask\n\nCan you tell me more about the company culture, especially within the clinical statistics and data analysis teams?\nWhat do you think are the most important attributes for someone in this role to succeed, particularly from an HR perspective?\n\n\n\nData Science & Information Management\nI have extensive experience working with large clinical datasets and transforming them into actionable insights. In my current role at CAPRISA, I’ve spearheaded the development of R-based pipelines, drastically reducing the time it takes to generate tables, listings, and figures (TLFs) for clinical trials by over 90%. I’m comfortable working with various programming languages, including R, Python, and SAS, and have built interactive dashboards using R Shiny and Power BI. I’m very excited about the potential to work with the Data Science and Information Management team at Mediclinic, where I could leverage my expertise in healthcare data analytics to create robust data solutions and contribute to improving clinical performance.\nKey Focus\n\nTechnical expertise with R, Python, SAS, and dashboard development.\nFocus on efficiency gains and scalable solutions for data analytics.\nStrong interest in collaborating with the Data Science team to enhance clinical performance.\n\nQuestions to Ask\n\nHow does the Data Science and Information Management team collaborate with the clinical statistics team? What opportunities are there for cross-functional projects?\nCould you share some examples of the key challenges the department is facing with clinical data management and performance measurement?\n\n\n\nClinical Data Intelligence\nI’ve always been deeply involved in the intersection of data analytics and clinical performance measurement. At CAPRISA, I worked closely with clinical teams to ensure that our statistical insights directly contributed to improved patient outcomes. For instance, I led several data initiatives during the COVID-19 pandemic, providing timely reports that informed public health decisions. I also collaborated with clinical researchers to ensure that our data solutions matched their specific needs, building dashboards that were both user-friendly and informative. This experience has equipped me with the skills to translate clinical requirements into technical specifications, something I’m eager to bring to Mediclinic. I’m passionate about leveraging data intelligence to drive better clinical outcomes.\nKey Focus\n\nExperience with clinical performance measurement.\nProven ability to translate clinical needs into data-driven solutions.\nEager to collaborate with the Clinical Data Intelligence team to improve patient outcomes.\n\nQuestions to Ask\n\nCould you share insights on the current clinical performance measurement strategies at Mediclinic and how this role will contribute to refining them?\nWhat are some of the immediate priorities for the Clinical Data Intelligence team that this role will support?\n\n\n\nActuarial Specialist\nI’ve worked extensively with large datasets and applied statistical models to not only analyze but also predict clinical outcomes. My work often involves risk analysis, especially when it comes to public health and clinical trials. I have a strong understanding of actuarial principles and how they intersect with healthcare statistics. For example, in a recent project on tuberculosis, I helped develop models that predicted drug-resistant cases, directly impacting patient treatment protocols. I’m excited about the opportunity to collaborate with someone like you, who brings an actuarial perspective to clinical data, and I believe my skills in predictive modeling and data analytics would complement your expertise perfectly.\nKey Focus\n\nEmphasize predictive modeling and statistical analysis for risk management.\nHighlight alignment with actuarial methods in improving clinical outcomes.\nInterest in collaboration with an actuarial specialist to enhance data-driven decision-making.\n\nQuestions to Ask\n\nHow do actuarial insights contribute to the clinical outcomes measured by the statistics team?\nAre there opportunities to integrate actuarial science and clinical statistics more closely in decision-making processes?\n\n\n\nOverall Approach\n\nAlign each panel member’s role and interests with specific strengths from your resume.\nFocus on how your skills and experience can directly support their work and Mediclinic’s overall goals.\nMaintain a narrative that reflects your enthusiasm and readiness to bring value to the team."
  },
  {
    "objectID": "tabs/research/PhD/sections/proposal.html",
    "href": "tabs/research/PhD/sections/proposal.html",
    "title": "A Bayesian Pharmacometric Machine Learning Framework for Integrating Historical Controls in Drug Development",
    "section": "",
    "text": "The development of new drugs is a complex, costly, and ethically challenging endeavor, with clinical trials playing a critical role in assessing drug efficacy and safety (Friedman, Furberg, and DeMets 2010) . Traditionally, these trials often involve control groups receiving placebo or standard treatment, raising ethical concerns and recruitment challenges, particularly when effective therapies already exist . The reliance on concurrent control groups in randomized controlled trials (RCTs) can lead to delays in drug development, increased costs, and potential ethical dilemmas when withholding potentially effective treatments from patients (Pocock 2013).\nTo address these issues, leveraging historical control data (HCD) from previous studies has gained significant interest (Berry and Hardwick 1994; Marion and Althouse 2023). HCD offers the potential to reduce the need for placebo or standard treatment arms, thereby minimizing patient burden and accelerating drug development timelines (Viele et al. 2013; Lim et al. 2019). By incorporating data from past trials, researchers can make more informed decisions about the effectiveness and safety of new interventions, potentially leading to faster approval and access to new treatments (Hall et al. 2020). The use of HCD can be particularly valuable in rare diseases or small patient populations where recruiting a sufficient number of participants for a traditional RCT may be difficult (Ghadessi et al. 2020).\nHowever, the heterogeneity and potential biases inherent in HCD, such as variations in patient populations, study designs, outcome measures, and potential publication or selection biases, present significant obstacles to their seamless integration (Schmidli et al. 2014; Branders et al. 2021). Differences in inclusion/exclusion criteria, disease severity, concomitant medications, and data collection methods can all contribute to heterogeneity, making direct comparisons challenging (Hall et al. 2020). Additionally, the quality of HCD can vary considerably, with some studies lacking adequate documentation or reporting, further complicating the integration process.\nBayesian statistics, pharmacometric modeling, and machine learning offer a synergistic approach to address these challenges. Bayesian methods provide a flexible framework for incorporating prior information, such as HCD, into current analyses, allowing for the updating of beliefs about treatment effects as new data becomes available (Jin et al. 2023). Pharmacometric models can be integrated with Bayesian methods to capture complex dose-response relationships, account for inter-individual variability, and predict treatment outcomes (Wakefield 1996; Lunn 2005). Machine learning algorithms can aid in identifying relevant HCD, given their ability to detect patterns and relationships within data, and improving the predictive accuracy of models (Lee et al. 2020).\nThe proposed framework aims to synergize these approaches to create a comprehensive solution for integrating HCD in drug development. By addressing challenges related to data selection, weighting, model integration, and regulatory alignment, this research aims to develop and validate a robust tool for integrating HCD, ultimately contributing to more efficient and ethical drug development processes."
  },
  {
    "objectID": "tabs/research/PhD/sections/proposal.html#introduction",
    "href": "tabs/research/PhD/sections/proposal.html#introduction",
    "title": "A Bayesian Pharmacometric Machine Learning Framework for Integrating Historical Controls in Drug Development",
    "section": "",
    "text": "The development of new drugs is a complex, costly, and ethically challenging endeavor, with clinical trials playing a critical role in assessing drug efficacy and safety (Friedman, Furberg, and DeMets 2010) . Traditionally, these trials often involve control groups receiving placebo or standard treatment, raising ethical concerns and recruitment challenges, particularly when effective therapies already exist . The reliance on concurrent control groups in randomized controlled trials (RCTs) can lead to delays in drug development, increased costs, and potential ethical dilemmas when withholding potentially effective treatments from patients (Pocock 2013).\nTo address these issues, leveraging historical control data (HCD) from previous studies has gained significant interest (Berry and Hardwick 1994; Marion and Althouse 2023). HCD offers the potential to reduce the need for placebo or standard treatment arms, thereby minimizing patient burden and accelerating drug development timelines (Viele et al. 2013; Lim et al. 2019). By incorporating data from past trials, researchers can make more informed decisions about the effectiveness and safety of new interventions, potentially leading to faster approval and access to new treatments (Hall et al. 2020). The use of HCD can be particularly valuable in rare diseases or small patient populations where recruiting a sufficient number of participants for a traditional RCT may be difficult (Ghadessi et al. 2020).\nHowever, the heterogeneity and potential biases inherent in HCD, such as variations in patient populations, study designs, outcome measures, and potential publication or selection biases, present significant obstacles to their seamless integration (Schmidli et al. 2014; Branders et al. 2021). Differences in inclusion/exclusion criteria, disease severity, concomitant medications, and data collection methods can all contribute to heterogeneity, making direct comparisons challenging (Hall et al. 2020). Additionally, the quality of HCD can vary considerably, with some studies lacking adequate documentation or reporting, further complicating the integration process.\nBayesian statistics, pharmacometric modeling, and machine learning offer a synergistic approach to address these challenges. Bayesian methods provide a flexible framework for incorporating prior information, such as HCD, into current analyses, allowing for the updating of beliefs about treatment effects as new data becomes available (Jin et al. 2023). Pharmacometric models can be integrated with Bayesian methods to capture complex dose-response relationships, account for inter-individual variability, and predict treatment outcomes (Wakefield 1996; Lunn 2005). Machine learning algorithms can aid in identifying relevant HCD, given their ability to detect patterns and relationships within data, and improving the predictive accuracy of models (Lee et al. 2020).\nThe proposed framework aims to synergize these approaches to create a comprehensive solution for integrating HCD in drug development. By addressing challenges related to data selection, weighting, model integration, and regulatory alignment, this research aims to develop and validate a robust tool for integrating HCD, ultimately contributing to more efficient and ethical drug development processes."
  },
  {
    "objectID": "tabs/research/PhD/sections/proposal.html#rationale",
    "href": "tabs/research/PhD/sections/proposal.html#rationale",
    "title": "A Bayesian Pharmacometric Machine Learning Framework for Integrating Historical Controls in Drug Development",
    "section": "Rationale",
    "text": "Rationale\nThe rationale for this research is to address the critical need for a robust and efficient framework for integrating historical control data (HCD) in drug development. By leveraging Bayesian statistics, pharmacometric modeling, and machine learning, this research aims to overcome the challenges associated with HCD heterogeneity and potential biases. The successful development and validation of such a framework would have significant implications for accelerating drug development timelines, reducing patient burden, and improving the ethical conduct of clinical trials. Furthermore, this research could contribute to more informed decision-making in drug development, ultimately leading to faster access to safe and effective therapies for patients in need."
  },
  {
    "objectID": "tabs/research/PhD/sections/proposal.html#aim-and-objectives",
    "href": "tabs/research/PhD/sections/proposal.html#aim-and-objectives",
    "title": "A Bayesian Pharmacometric Machine Learning Framework for Integrating Historical Controls in Drug Development",
    "section": "Aim and Objectives",
    "text": "Aim and Objectives\nThe overarching aim of this research is to develop and validate a Bayesian pharmacometric machine learning framework for the integration of historical control data (HCD) in drug development, thereby enhancing the efficiency, ethical conduct, and decision-making processes within clinical trials.\nTo achieve this overarching aim, the following specific objectives will be pursued:\n\nA unified framework will be constructed, integrating Bayesian statistics, pharmacometric modeling, and machine learning algorithms. This framework will facilitate the quantification of uncertainty, the prediction of treatment effects based on HCD, and the identification of patterns and relationships within the HCD.\nAlgorithms will be designed and implemented to identify and select relevant HCD based on their similarity to the current trial population, while accounting for potential biases and heterogeneity. Furthermore, methods will be developed to optimally weight HCD based on their relevance and informativeness, ensuring that the most pertinent data influence the analysis.\nPharmacokinetic/pharmacodynamic (PK/PD) modeling will be incorporated into the framework to predict treatment effects in the current trial population based on HCD. This integration will involve adjusting for differences in patient characteristics and disease progression to ensure accurate and contextually relevant predictions.\n\n\nAdditional Objectives\n\nThe potential of the proposed framework to enable adaptive trial design adjustments will be investigated. This exploration will focus on utilizing accumulating HCD to potentially reduce sample size requirements while maintaining statistical rigor and ethical considerations.\nThe regulatory implications of using HCD in clinical trials will be thoroughly investigated to ensure compliance with guidelines from agencies such as the FDA and EMA. The framework will undergo rigorous validation to ensure its reliability and robustness for decision-making, providing a solid foundation for regulatory acceptance and practical implementation."
  },
  {
    "objectID": "tabs/research/PhD/sections/proposal.html#methodology",
    "href": "tabs/research/PhD/sections/proposal.html#methodology",
    "title": "A Bayesian Pharmacometric Machine Learning Framework for Integrating Historical Controls in Drug Development",
    "section": "Methodology",
    "text": "Methodology\nThe proposed research will be conducted through a multi-phase approach, encompassing the development, validation, and application of a Bayesian pharmacometric machine learning (BPML) framework for integrating historical control data (HCD) in clinical trials. This methodology is designed to ensure the robust and reliable implementation of the framework, which synergistically combines Bayesian statistics, pharmacometric modeling, and machine learning algorithms.\n\nPhase 1: Framework Construction\nThe initial phase involves the construction of the unified BPML framework. This will commence with a comprehensive literature review to identify existing methodologies and potential gaps in the integration of HCD in drug development (e.g., Viele et al. (2013)). Bayesian statistical methods will form the foundation of the framework, allowing for the incorporation of prior information and the quantification of uncertainty (Schmidli et al. 2014). Pharmacometric models, specifically pharmacokinetic/pharmacodynamic (PK/PD) models, will be integrated to capture the complex dynamics of drug effects and disease progression (Mould and Upton 2013). Machine learning algorithms will be employed to identify patterns and relationships within the HCD, facilitating the prediction of treatment effects (Vamathevan et al. 2019).\n\n\nPhase 2: Algorithm Design\nIn this phase, algorithms will be designed to identify and select relevant HCD. This involves the development of similarity metrics to match historical controls to the current trial population, accounting for demographic and clinical characteristics, disease states, and other pertinent variables. Advanced machine learning techniques, such as clustering and classification algorithms, will be utilized to manage the heterogeneity and potential biases inherent in historical data (Schmidli et al. 2014). Methods for optimally weighting HCD will be developed, ensuring that the analysis is influenced by the most relevant and informative data. This weighting process will leverage Bayesian hierarchical models to balance the contributions of various data sources (Schmidli et al. 2014).\n\n\nPhase 3: PK/PD Model Integration\nThe integration of PK/PD modeling within the framework will follow the identification and selection of HCD. This step involves adjusting the pharmacometric models to reflect the characteristics of the current trial population. Bayesian methods will be used to update these models with new data, providing contextually relevant predictions of treatment effects (Jin et al. 2023). The models will be calibrated using a combination of historical and current trial data, with careful attention to differences in patient characteristics and disease progression (Mould and Upton 2013).\n\n\nPhase 4: Framework Validation\nValidation of the framework will be conducted through a series of simulations and real-world case studies. Simulations will be designed to test the robustness of the framework under various scenarios, including different levels of data heterogeneity, varying sample sizes, and different degrees of similarity between historical and current trial populations. These simulations will help identify potential limitations and areas for improvement. Real-world case studies, involving actual clinical trial data, will provide practical insights into the framework’s performance and applicability. Metrics for validation will include predictive accuracy, the precision of uncertainty estimates, and the framework’s ability to improve decision-making processes in clinical trials.\n\n\nAdditional Phases\n\nPhase 5: Adaptive Trial Design Exploration\nThe framework will be examined for its capability to utilize accumulating HCD during ongoing trials, exploring the potential of adaptive trial design adjustments. This exploration will assess how real-time integration of HCD can inform interim analyses and potentially reduce sample size requirements while maintaining statistical rigor and ethical considerations. The framework’s flexibility and adaptability will be tested through simulations that mimic adaptive trial scenarios (Pallmann et al. 2018).\n\n\nPhase 6: Regulatory Compliance\nThe regulatory implications of using HCD in clinical trials will be thoroughly investigated to ensure compliance with guidelines from regulatory agencies such as the FDA and EMA (Beckett 2014; EMA 2014). The framework will undergo rigorous validation to ensure its reliability and robustness for decision-making, providing a solid foundation for regulatory acceptance and practical implementation."
  },
  {
    "objectID": "tabs/research/PhD/sections/proposal.html#ethical-considerations",
    "href": "tabs/research/PhD/sections/proposal.html#ethical-considerations",
    "title": "A Bayesian Pharmacometric Machine Learning Framework for Integrating Historical Controls in Drug Development",
    "section": "Ethical Considerations",
    "text": "Ethical Considerations\nThroughout the research, ethical considerations will be paramount. The integration of HCD aims to enhance the ethical conduct of clinical trials by potentially reducing the need for control groups and minimizing patient exposure to less effective treatments. The methodology will be designed to ensure transparency, reproducibility, and adherence to regulatory standards (Taylor, Rebok, and Marsiske 2022)."
  },
  {
    "objectID": "tabs/research/PhD/sections/proposal_narrowed.html",
    "href": "tabs/research/PhD/sections/proposal_narrowed.html",
    "title": "A Bayesian Pharmacometric Machine Learning Framework for Integrating Historical Controls in Drug Development",
    "section": "",
    "text": "The development of new drugs represents a multifaceted challenge, marked by complexity, significant costs, and pressing ethical considerations, with clinical trials serving as the pivotal mechanism for evaluating drug efficacy and safety (Friedman, Furberg, and DeMets 2010). Traditionally, these trials necessitate control groups that receive either a placebo or standard treatment, which can pose substantial ethical and recruitment hurdles, especially in scenarios where effective therapies are already in use. The reliance on concurrent control groups in randomized controlled trials (RCTs) often results in prolonged drug development periods, inflated costs, and ethical quandaries, particularly when it involves withholding potential treatments from patients (Pocock 2013).\nIn response to these challenges, the utilization of historical control data (HCD) from prior studies has emerged as a significant area of interest (Berry and Hardwick 1994; Marion and Althouse 2023). HCD holds the promise of diminishing the need for placebo or standard treatment arms, thus reducing patient burden and expediting drug development timelines (Viele et al. 2013; Lim et al. 2019). By integrating data from previous trials, researchers can make more informed decisions regarding the effectiveness and safety of new interventions, potentially facilitating quicker approvals and access to novel treatments (Hall et al. 2020). This approach is especially valuable in the context of rare diseases or small patient populations, where assembling a sufficient number of participants for a traditional RCT may prove challenging (Ghadessi et al. 2020).\nHowever, the intrinsic heterogeneity and potential biases in HCD, such as variations in patient demographics, study designs, outcome measures, and potential publication or selection biases, pose substantial challenges to their straightforward integration (Schmidli et al. 2014; Branders et al. 2021). Discrepancies in inclusion/exclusion criteria, disease severity, concurrent medications, and data collection methods can all contribute to this heterogeneity, making direct comparisons arduous (Hall et al. 2020). Moreover, the quality of HCD can vary significantly, with some studies lacking adequate documentation or comprehensive reporting, further complicating the integration process.\nTo navigate these complexities, a synergistic approach combining Bayesian statistics, pharmacometric modeling, and machine learning is proposed. Bayesian methods provide a flexible framework that facilitates the integration of prior information, such as HCD, allowing for continuous updates in treatment effect beliefs as new data becomes available (Jin et al. 2023). Pharmacometric models, which are adept at capturing the dynamic interplay between drug action and disease progression, can be integrated with Bayesian methods to account for inter-individual variability and predict treatment outcomes (Wakefield 1996; Lunn 2005). Additionally, machine learning algorithms can enhance the selection and validation of relevant HCD by detecting patterns and relationships within data, thus improving the predictive accuracy of models (Lee et al. 2020).\nThis proposed research aims to unify these methodologies into a comprehensive framework for integrating HCD in drug development. By addressing challenges related to data selection, weighting, model integration, and regulatory alignment, this initiative strives to develop and validate a robust tool for incorporating HCD, ultimately contributing to more efficient and ethically sound drug development processes."
  },
  {
    "objectID": "tabs/research/PhD/sections/proposal_narrowed.html#introduction",
    "href": "tabs/research/PhD/sections/proposal_narrowed.html#introduction",
    "title": "A Bayesian Pharmacometric Machine Learning Framework for Integrating Historical Controls in Drug Development",
    "section": "",
    "text": "The development of new drugs represents a multifaceted challenge, marked by complexity, significant costs, and pressing ethical considerations, with clinical trials serving as the pivotal mechanism for evaluating drug efficacy and safety (Friedman, Furberg, and DeMets 2010). Traditionally, these trials necessitate control groups that receive either a placebo or standard treatment, which can pose substantial ethical and recruitment hurdles, especially in scenarios where effective therapies are already in use. The reliance on concurrent control groups in randomized controlled trials (RCTs) often results in prolonged drug development periods, inflated costs, and ethical quandaries, particularly when it involves withholding potential treatments from patients (Pocock 2013).\nIn response to these challenges, the utilization of historical control data (HCD) from prior studies has emerged as a significant area of interest (Berry and Hardwick 1994; Marion and Althouse 2023). HCD holds the promise of diminishing the need for placebo or standard treatment arms, thus reducing patient burden and expediting drug development timelines (Viele et al. 2013; Lim et al. 2019). By integrating data from previous trials, researchers can make more informed decisions regarding the effectiveness and safety of new interventions, potentially facilitating quicker approvals and access to novel treatments (Hall et al. 2020). This approach is especially valuable in the context of rare diseases or small patient populations, where assembling a sufficient number of participants for a traditional RCT may prove challenging (Ghadessi et al. 2020).\nHowever, the intrinsic heterogeneity and potential biases in HCD, such as variations in patient demographics, study designs, outcome measures, and potential publication or selection biases, pose substantial challenges to their straightforward integration (Schmidli et al. 2014; Branders et al. 2021). Discrepancies in inclusion/exclusion criteria, disease severity, concurrent medications, and data collection methods can all contribute to this heterogeneity, making direct comparisons arduous (Hall et al. 2020). Moreover, the quality of HCD can vary significantly, with some studies lacking adequate documentation or comprehensive reporting, further complicating the integration process.\nTo navigate these complexities, a synergistic approach combining Bayesian statistics, pharmacometric modeling, and machine learning is proposed. Bayesian methods provide a flexible framework that facilitates the integration of prior information, such as HCD, allowing for continuous updates in treatment effect beliefs as new data becomes available (Jin et al. 2023). Pharmacometric models, which are adept at capturing the dynamic interplay between drug action and disease progression, can be integrated with Bayesian methods to account for inter-individual variability and predict treatment outcomes (Wakefield 1996; Lunn 2005). Additionally, machine learning algorithms can enhance the selection and validation of relevant HCD by detecting patterns and relationships within data, thus improving the predictive accuracy of models (Lee et al. 2020).\nThis proposed research aims to unify these methodologies into a comprehensive framework for integrating HCD in drug development. By addressing challenges related to data selection, weighting, model integration, and regulatory alignment, this initiative strives to develop and validate a robust tool for incorporating HCD, ultimately contributing to more efficient and ethically sound drug development processes."
  },
  {
    "objectID": "tabs/research/PhD/sections/proposal_narrowed.html#rationale",
    "href": "tabs/research/PhD/sections/proposal_narrowed.html#rationale",
    "title": "A Bayesian Pharmacometric Machine Learning Framework for Integrating Historical Controls in Drug Development",
    "section": "Rationale",
    "text": "Rationale\nThe rationale for this research is rooted in the critical need for a robust and efficient method to integrate historical control data (HCD) in drug development. By harnessing the capabilities of Bayesian statistics, pharmacometric modeling, and machine learning, this research aims to address the inherent challenges of heterogeneity and biases within HCD. Successful development and validation of this framework could significantly accelerate drug development timelines, reduce patient burden, and improve the ethical conduct of clinical trials. Moreover, this research promises to enhance decision-making processes in drug development, ultimately enabling quicker access to safe and effective treatments for patients."
  },
  {
    "objectID": "tabs/research/PhD/sections/proposal_narrowed.html#aim-and-objectives",
    "href": "tabs/research/PhD/sections/proposal_narrowed.html#aim-and-objectives",
    "title": "A Bayesian Pharmacometric Machine Learning Framework for Integrating Historical Controls in Drug Development",
    "section": "Aim and Objectives",
    "text": "Aim and Objectives\nTo develop and validate a Bayesian pharmacometric machine learning framework that integrates historical control data in drug development, thereby improving efficiency, ethical standards, and decision-making in clinical trials.\nTo achieve this overarching aim, the following specific objectives will be pursued:\n\nConstruct a unified framework combining Bayesian statistics, pharmacometric modeling, and machine learning algorithms to facilitate the quantification of uncertainty, predict treatment effects using HCD, and identify patterns and relationships within the data.\nDesign and implement algorithms to accurately identify and select relevant HCD based on their similarity to the current trial population, while accounting for potential biases and heterogeneity.\nIncorporate pharmacokinetic/pharmacodynamic (PK/PD) modeling into the framework to predict treatment effects in the current trial population accurately, adjusting for patient characteristics and disease progression.\n\n\nAdditional Objectives\n\nInvestigate the framework’s potential to enable adaptive trial design adjustments, focusing on utilizing accumulating HCD to potentially reduce sample size requirements while maintaining statistical rigor and ethical considerations.\nExamine the regulatory implications of using HCD in clinical trials to ensure compliance with guidelines from agencies such as the FDA and EMA. Validate the framework thoroughly to ensure its reliability and robustness for decision-making."
  },
  {
    "objectID": "tabs/research/PhD/sections/proposal_narrowed.html#methodology",
    "href": "tabs/research/PhD/sections/proposal_narrowed.html#methodology",
    "title": "A Bayesian Pharmacometric Machine Learning Framework for Integrating Historical Controls in Drug Development",
    "section": "Methodology",
    "text": "Methodology\nThe proposed research will follow a multi-phase approach, ensuring the robust and reliable implementation of the Bayesian pharmacometric machine learning (BPML) framework for integrating historical control data in clinical trials.\n\nPhase 1: Framework Construction\n\nBegin with a comprehensive literature review to identify existing methodologies and pinpoint gaps in integrating HCD in drug development.\nDevelop the foundation of the framework using Bayesian statistical methods to incorporate prior information and quantify uncertainty.\nIntegrate pharmacometric models to capture the complex dynamics of drug effects and disease progression.\nEmploy machine learning algorithms to detect patterns and predict treatment effects based on HCD.\n\n\n\nPhase 2: Algorithm Design\n\nDevelop algorithms for identifying and selecting relevant HCD, using similarity metrics and advanced machine learning techniques to manage heterogeneity and biases.\nDesign methods for optimally weighting HCD, employing Bayesian hierarchical models to balance the contributions of various data sources.\n\n\n\nPhase 3: PK/PD Model Integration\n\nIntegrate PK/PD modeling within the framework following the identification and selection of HCD, adjusting models to reflect the characteristics of the current trial population.\nUse Bayesian methods to update models with new data, providing contextually relevant predictions of treatment effects.\n\n\n\nPhase 4: Framework Validation\n\nConduct simulations and real-world case studies to validate the framework, testing its robustness under various scenarios and providing practical insights into its performance and applicability.\n\n\n\nAdditional Phases\n\nPhase 5: Adaptive Trial Design Exploration\n\nExplore the framework’s capability to utilize accumulating HCD during ongoing trials to inform interim analyses and potentially reduce sample size requirements.\n\n\n\nPhase 6: Regulatory Compliance\n\nInvestigate the regulatory implications of using HCD, ensuring the framework’s compliance with guidelines and its reliability for decision-making."
  },
  {
    "objectID": "tabs/research/PhD/sections/proposal_narrowed.html#ethical-considerations",
    "href": "tabs/research/PhD/sections/proposal_narrowed.html#ethical-considerations",
    "title": "A Bayesian Pharmacometric Machine Learning Framework for Integrating Historical Controls in Drug Development",
    "section": "Ethical Considerations",
    "text": "Ethical Considerations\nThroughout the research, ethical considerations will be paramount. The integration of HCD aims to enhance the ethical conduct of clinical trials by potentially reducing the need for control groups and minimizing patient exposure to less effective treatments. The methodology will be designed to ensure transparency, reproducibility, and adherence to regulatory standards (Taylor, Rebok, and Marsiske 2022)."
  },
  {
    "objectID": "tabs/research/PhD/sections/proposal_narrowed.html#references",
    "href": "tabs/research/PhD/sections/proposal_narrowed.html#references",
    "title": "A Bayesian Pharmacometric Machine Learning Framework for Integrating Historical Controls in Drug Development",
    "section": "References",
    "text": "References\nAim and Objectives The overarching aim of this research is to develop and validate a Bayesian pharmacometric machine learning framework for the integration of historical control data (HCD) in drug development, thereby enhancing the efficiency, ethical conduct, and decision-making processes within clinical trials.\nTo achieve this overarching aim, the following specific objectives will be pursued:\nFramework Development: Construct a unified Bayesian pharmacometric machine learning (BPML) framework that integrates Bayesian statistics and machine learning algorithms to facilitate the effective integration of HCD in clinical trials. Algorithm Design for HCD Selection and Weighting: Develop and implement algorithms to identify and select relevant HCD based on their similarity to the current trial population, while accounting for potential biases and heterogeneity. Design methods to optimally weight HCD, ensuring that the most pertinent data influence the analysis. Verification of HCD Comparability Using Machanistic Pharmacometric Models: Integrate pharmacometric models to verify the comparability of selected HCD with the current trial data ensuring that HCD accurately reflects disease dynamics and biological Machanistic observed in the current trial population. Biostatistical Model Integration for Treatment Effect Prediction: Integrate common biostatistical models into the framework to evaluate the efficacy and safety of treatments based on the verified HCD. The objective is to ensure the selected HCD and the trial cohort are providing a comprehensive assessment of treatment effects as expected using robust biostatistical techniques. Adaptive Trial Design Exploration: Investigate the potential of the BPML framework to enable adaptive trial design adjustments, utilizing accumulating HCD to potentially reduce sample size requirements while maintaining statistical rigor and ethical considerations."
  },
  {
    "objectID": "tabs/research/PhD/phd_proposal_abstract.html",
    "href": "tabs/research/PhD/phd_proposal_abstract.html",
    "title": "PhD Proposal Abstract",
    "section": "",
    "text": "A Bayesian Machine Learning Framework for Integrating Historical Controls and Pharmacometric Models in Drug Development"
  },
  {
    "objectID": "tabs/research/PhD/phd_proposal_abstract.html#phd-proposal-title",
    "href": "tabs/research/PhD/phd_proposal_abstract.html#phd-proposal-title",
    "title": "PhD Proposal Abstract",
    "section": "",
    "text": "A Bayesian Machine Learning Framework for Integrating Historical Controls and Pharmacometric Models in Drug Development"
  },
  {
    "objectID": "tabs/research/PhD/phd_proposal_abstract.html#proposal-description",
    "href": "tabs/research/PhD/phd_proposal_abstract.html#proposal-description",
    "title": "PhD Proposal Abstract",
    "section": "Proposal Description:",
    "text": "Proposal Description:\nThis research addresses a pivotal challenge in modern drug development: the effective and ethical utilization of historical control data (HCD) in clinical trials. HCD, encompassing data from past trials, offers invaluable insights into disease natural history, treatment response variability, and potential safety signals. Leveraging HCD has the potential to streamline clinical trials, reduce costs, and minimize patient exposure to potentially ineffective or harmful interventions (Mistry et al., 2021). The growing recognition of this potential is evidenced by the increasing acceptance of HCD by regulatory agencies like the FDA and EMA, particularly in rare diseases or situations where large control groups are difficult to recruit (Food and Drug Administration, 2018; European Medicines Agency, 2017).\nDespite this growing acceptance, several challenges hinder the seamless integration of HCD. Concerns regarding data heterogeneity, bias stemming from differences in study design, patient populations, or treatment standards, and the evolving nature of clinical practice pose significant hurdles (Schmidli et al., 2014). Additionally, the statistical complexity of analyzing HCD often necessitates sophisticated methodologies that may not be readily accessible to all researchers. Ethical considerations regarding patient consent and the potential for denying patients access to novel treatments further complicate the landscape (van der Graaf et al., 2020).\nTo address these multifaceted challenges, this research proposes the development of a robust and flexible Bayesian machine learning framework. This framework will systematically integrate HCD and pharmacometric models (PMMs) to enhance the efficiency and informativeness of clinical trials while rigorously quantifying uncertainties and risks."
  },
  {
    "objectID": "tabs/research/PhD/phd_proposal_abstract.html#key-objectives",
    "href": "tabs/research/PhD/phd_proposal_abstract.html#key-objectives",
    "title": "PhD Proposal Abstract",
    "section": "Key Objectives:",
    "text": "Key Objectives:\n\nIntelligent Selection and Weighting of HCD (with ML): Leverage a synergistic combination of Bayesian methods and advanced machine learning techniques to develop algorithms that intelligently identify, select, and weight the most relevant HCD. This will involve:\n\n\nSupervised and Unsupervised Learning: Employing algorithms like random forests (Breiman, 2001) and gradient boosting (Friedman, 2001) to predict HCD relevance based on patient characteristics, trial design, and other relevant features. Unsupervised techniques such as clustering or dimensionality reduction (Van Der Maaten & Hinton, 2008) will be used to identify patterns and group similar trials.\nNatural Language Processing (NLP): Utilizing NLP techniques (e.g., transformer models like BERT; Devlin et al., 2018) to extract pertinent information from unstructured text data (e.g., clinical trial reports) to assess HCD quality and identify relevant details.\nReinforcement Learning: Exploring the potential of reinforcement learning (Sutton & Barto, 2018) to create agents capable of learning and optimizing HCD selection and weighting strategies over time.\nBayesian Optimization, BNNs, and PGMs: Integrating Bayesian techniques like optimization (Snoek et al., 2012), neural networks (Neal, 1996), and graphical models (Koller & Friedman, 2009) to enhance the efficiency, flexibility, and uncertainty quantification of the HCD selection process.\n\n\nIntegration of Pharmacometric Models (PMMs): Incorporate PMMs into the Bayesian framework, recognizing their unique ability to capture the complex dynamics of disease progression and drug effects over time. Unlike simpler longitudinal models, PMMs offer a mechanistic understanding of disease processes, explicitly account for drug effects and inter-individual variability, and have superior predictive power for both treated and untreated disease trajectories (Mould & Upton, 2012). By integrating PMMs, the framework will leverage a deeper understanding of disease mechanisms to enhance predictions of treatment outcomes.\nQuantification of Uncertainty and Risk: Employ Bayesian methods to rigorously quantify uncertainty in the predictions and inferences made from the HCD and PMMs. This quantification will facilitate more informed decision-making, enabling a balanced assessment of the potential benefits of new treatments against their risks (O’Hagan et al., 2006)."
  },
  {
    "objectID": "tabs/research/PhD/phd_proposal_abstract.html#research-questions",
    "href": "tabs/research/PhD/phd_proposal_abstract.html#research-questions",
    "title": "PhD Proposal Abstract",
    "section": "Research Questions:",
    "text": "Research Questions:\n\nHow can a combination of Bayesian and machine learning methods be most effectively leveraged to identify and weight the most relevant HCD?\nWhat are the optimal strategies for integrating pharmacometric models into a Bayesian framework to enhance the prediction of treatment outcomes?\nWhat are the best approaches for quantifying and communicating uncertainty and risk associated with using HCD and PMMs to inform decision-making?"
  },
  {
    "objectID": "tabs/research/PhD/phd_proposal_abstract.html#references",
    "href": "tabs/research/PhD/phd_proposal_abstract.html#references",
    "title": "PhD Proposal Abstract",
    "section": "References:",
    "text": "References:\n\nBerry, D. A. (2006). Bayesian clinical trials. Nature Reviews Drug Discovery, 5(1), 27-36.\nBreiman, L. (2001). Random forests. Machine Learning, 45(1), 5-32.\nDevlin, J., Chang, M. W., Lee, K., & Toutanova, K. (2018). BERT: Pre-training of deep bidirectional transformers for language understanding. arXiv preprint arXiv:1810.04805.\nEuropean Medicines Agency. (2017). Guideline on the choice of the non-inferiority margin.\nFood and Drug Administration. (2018). Use of historical control data in clinical trials guidance for industry.\nFriedman, J. H. (2001). Greedy function approximation: A gradient boosting machine. Annals of Statistics, 29(5), 1189-1232.\nJaroszewski, L., et al. (2021). Creating a historical control repository for regulatory decision-making: learnings and experiences from a multi-stakeholder collaboration. Therapeutic Innovation & Regulatory Science, 55(3), 437-444.\nKoller, D., & Friedman, N. (2009). Probabilistic graphical models: Principles and techniques. MIT Press.\nMistry, H., et al. (2021). The use of historical control data in clinical trials: A systematic review. Contemporary Clinical Trials, 101, 106269.\nMould, D. R., & Upton, R. N. (2012). Basic concepts in population modeling, simulation, and model-based drug development. CPT: Pharmacometrics & Systems Pharmacology, 1(9), e6.\nNeal, R. M. (1996). Bayesian learning for neural networks. Springer Science & Business Media.\nO’Hagan, A., Buck, C. E., Daneshkhah, A., Eiser, J. R., Garthwaite, P. H., Jenkinson, D. J., … & Rakow, T. (2006). Uncertain judgements: Eliciting experts’ probabilities. John Wiley & Sons.\nSchmidli, H., Gsteiger, S., Roychoudhury, S., O’Hagan, A., Spiegelhalter, D., & Neuenschwander, B. (2014). Robust meta-analytic-predictive priors in clinical trials with historical control information. Biometrics, 70(4), 1023-1032.\nSnoek, J., Larochelle, H., & Adams, R. P. (2012). Practical Bayesian optimization of machine learning algorithms. In Advances in Neural Information Processing Systems (pp. 2951-2959).\nSpiegelhalter, D. J., Abrams, K. R., & Myles, J. P. (2004). Bayesian approaches to clinical trials and health-care evaluation. John Wiley & Sons.\nSutton, R. S., & Barto, A. G. (2018). Reinforcement learning: An introduction. MIT Press.\nvan der Graaf, R., et al. (2020). Ethical considerations in the use of historical control data in clinical trials. BMC Medical Ethics, 21(1), 1-9.\nVan Der Maaten, L., & Hinton, G. (2008). Visualizing data using t-SNE. Journal of Machine Learning Research, 9(11).\nViele, K., et al. (2014). Use of historical control data for assessing treatment effects in clinical trials. Pharmaceutical Statistics, 13(1), 41-54."
  },
  {
    "objectID": "tabs/trainings/trainings.html",
    "href": "tabs/trainings/trainings.html",
    "title": "Materials",
    "section": "",
    "text": "A series of materials in the form of Notes and/or Presentation for specific Project are provided here."
  },
  {
    "objectID": "tabs/resume/Marothi_Peter_Letsoalo_Resume.html",
    "href": "tabs/resume/Marothi_Peter_Letsoalo_Resume.html",
    "title": "Resume",
    "section": "",
    "text": "Email: marothi.letsoalo.001@gmail.com\nLinkedIn: Professional LinkedIn Profile\nPhone: +27 (81) 512-7839\nLocation: Little Falls, Johannesburg\n\nBirthplace: Mankweng, South Africa\nNationality: South African\nGender: Male\nCivil Status: Married\nI am a biostatistician and data scientist contributing to people’s health through clinical research through with data and science. My passion is driven by a continuous need for precision public health as well as precision medicine. I have extensive experience in designing, analyzing, and reporting on various types of clinical trials and cohort studies, using advanced biostatistics and bioinformatic methods. I also have strong skills in data management and programming, as well as in writing scientific manuscripts and presenting statistical results. Recently acquired extensive skill in in pharmacometrics. I enjoy collaborating with multidisciplinary teams of scientists, and principal investigators, as well as mentoring and training junior statisticians. Highlight of my field of knowledge and technical skills:\nField\nClinical Research | Drug Development | Clinical Trials | Biostatistics | Pharmacometrics | Data Science |\nSkills\nStatistical Programming, Analysis & Modelling (R, SAS) | Bioinformatics Analysis (R, Python) | Data Science & Machine Learning (R, Python) | Pharmacometrics (R, Phoenix, NONMEM) | Clinical Data Management & Processing (R, Python, SAS, SQL)"
  },
  {
    "objectID": "tabs/resume/Marothi_Peter_Letsoalo_Resume.html#work-experience",
    "href": "tabs/resume/Marothi_Peter_Letsoalo_Resume.html#work-experience",
    "title": "Resume",
    "section": "Work Experience",
    "text": "Work Experience\nSenior Biostatistician, CAPRISA, Durban, South Africa (1/2021 to Present)\nProvide and participate in study design, sample size determination, randomization procedures, periodic reports, statistical plans, and statistical analysis on multiple clinical trials.\n\nDesign and analysis of clinical trials.\nCo-author of scientific manuscripts.\nStatistical analysis and methodological input on clinical data.\nSupervision and training of junior statisticians.\n\nResearch Data Manager, VLIR-OUS, University of Limpopo, South Africa (6/2016 to 3/2019)\nPlayed a key role as research data manager; extracting and analyzing complex data, while ensuring clean data demands long working hours and patience.\n\nManaged and analyzed complex data.\nDeveloped databases and performed data cleaning.\nProvided training and support for data collection and analysis.\n\nJunior Lecturer, University of Limpopo, South Africa (1/2015 to 5/2016)\nInteracted daily with students, teaching introductory statistics and crafting detailed study guides and lecture notes.\n\nTaught introductory statistics.\nDeveloped educational materials and assessed student performance.\n\nFaculty Researcher, University of Limpopo, South Africa (4/2012 to 12/2014)\nConducted and completed evaluation programs of student data to explore students at risk.\n\nConducted research and data analysis.\nCo-authored a peer-reviewed paper."
  },
  {
    "objectID": "tabs/resume/Marothi_Peter_Letsoalo_Resume.html#education",
    "href": "tabs/resume/Marothi_Peter_Letsoalo_Resume.html#education",
    "title": "Resume",
    "section": "Education",
    "text": "Education\n\nPharmacometrics, Pharmacometrics Africa\nData Science and Machine Learning, MIT Schwarzman College of Computing, Cambridge, MA, USA\nMaster of Biostatistics (RSS accredited), Hasselt University, Diepenbeek, Belgium\nMaster of Science in Statistics, University of Limpopo, Mankweng, South Africa\nBSc (Hons) in Statistics, University of Limpopo, Mankweng, South Africa\nBSc in Applied Mathematics & Statistics, University of Limpopo, Mankweng, South Africa"
  },
  {
    "objectID": "tabs/resume/Marothi_Peter_Letsoalo_Resume.html#awards-and-honors",
    "href": "tabs/resume/Marothi_Peter_Letsoalo_Resume.html#awards-and-honors",
    "title": "Resume",
    "section": "Awards and Honors",
    "text": "Awards and Honors\n\nVLIR Scholarship for a Master in Biostatistics at UHasselt\nSecond best development relevant master’s thesis, UHasselt 2020 in the category international student"
  },
  {
    "objectID": "tabs/resume/Marothi_Peter_Letsoalo_Resume.html#certifications",
    "href": "tabs/resume/Marothi_Peter_Letsoalo_Resume.html#certifications",
    "title": "Resume",
    "section": "Certifications",
    "text": "Certifications\nPharmacometrics (PMx Africa)| Data Science and Machine Learning (MIT) Verify | Clinical Trials Programming Using SAS Verify | Advanced Programmer for SAS 9Verify | Base Programmer for SAS 9 Verify | Statistical Business Analyst Using SAS 9 Verify | VIARES Clinical Research Data Management]() | Design and Interpretation of Clinical Trials (John Hopkins University) Verify | ICH Good Clinical Practice E6 (R2) Verify | Designing Big Data Healthcare Studies: Part I- Verify | Part II-Verify"
  },
  {
    "objectID": "tabs/resume/Marothi_Peter_Letsoalo_Resume.html#projects",
    "href": "tabs/resume/Marothi_Peter_Letsoalo_Resume.html#projects",
    "title": "Resume",
    "section": "Projects",
    "text": "Projects\n\nCAPRISA Epidemic Intelligence Unit (2022-present): Lead biostatistician.\nAI-based HIV Prevention for Generation Z population (2022-present): Project coordinator."
  },
  {
    "objectID": "tabs/resume/Marothi_Peter_Letsoalo_Resume.html#publications",
    "href": "tabs/resume/Marothi_Peter_Letsoalo_Resume.html#publications",
    "title": "Resume",
    "section": "Publications",
    "text": "Publications\n\n\nBodley, Nicola, Jienchi Dorward, Jessica Naidoo, Marothi Letsoalo, Kaminee Ramsaroop, Fathima Sayed, Yukteshwar Sookrajh, Paul K. Drain, and Nigel Garrett. 2023. “Diagnostic Accuracy of the Alere Afinion AS100 Point-of-Care Assay to Screen for Noncommunicable Diseases Among People Living With HIV.” JAIDS Journal of Acquired Immune Deficiency Syndromes 92 (1): e1–3. https://doi.org/10.1097/qai.0000000000003098.\n\n\nDhindayal, Sherishka, Marothi P. Letsoalo, and Tanuja N. Gengiah. 2022. “Mental Health Outcomes and Workplace Quality of Life Among South African Pharmacists During the COVID-19 Pandemic: A Cross-Sectional Study.” Journal of Pharmaceutical Policy and Practice 15 (1). https://doi.org/10.1186/s40545-022-00463-7.\n\n\nGordhan, Bhavna G., Astika Sewcharran, Marothi Letsoalo, Thilgavathy Chinappa, Nonhlanhla Yende-Zuma, Nesri Padayatchi, Kogieleum Naidoo, and Bavesh D. Kana. 2022. “Detection of Differentially Culturable Tubercle Bacteria in Sputum from Drug-Resistant Tuberculosis Patients.” Frontiers in Cellular and Infection Microbiology 12 (September). https://doi.org/10.3389/fcimb.2022.949370.\n\n\nLale Ngema, Senamile, Navisha Dookie, Rubeshan Perumal, Louansha Nandlal, Nikita Naicker, Marothi Peter Letsoalo, Max O’Donnell, Azraa Khan, Nesri Padayatchi, and Kogieleum Naidoo. 2023. “Isoniazid Resistance-Conferring Mutations Are Associated with Highly Variable Phenotypic Resistance.” Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 33 (December): 100387. https://doi.org/10.1016/j.jctube.2023.100387.\n\n\nMaseko, Thando Glory, Slindile Ngubane, Marothi Letsoalo, Santhuri Rambaran, Derseree Archary, Natasha Samsunder, Rubeshan Perumal, et al. 2023. “Higher Plasma Interleukin -6 Levels Are Associated with Lung Cavitation in Drug-Resistant Tuberculosis.” BMC Immunology 24 (1). https://doi.org/10.1186/s12865-023-00563-2.\n\n\nPerumal, Rubeshan, Neda Bionghi, Camus Nimmo, Marothi Letsoalo, Matthew J. Cummings, Madeleine Hopson, Allison Wolf, et al. 2023. “Baseline and Treatment-Emergent Bedaquiline Resistance in Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis.” European Respiratory Journal 62 (6): 2300639. https://doi.org/10.1183/13993003.00639-2023.\n\n\nPerumal, Rubeshan, Kogieleum Naidoo, Anushka Naidoo, Marothi P. Letsoalo, Aliasgar Esmail, Ivan Joubert, Paolo Denti, et al. 2023. “The Impact of Enteral Feeding and Therapeutic Monitoring of Rifampicin with Dose Escalation in Critically Ill Patients with Tuberculosis.” International Journal of Infectious Diseases 126 (January): 174–80. https://doi.org/10.1016/j.ijid.2022.11.033.\n\n\nPillay, Nashlin, Gugulethu Favourate Mzobe, Marothi Letsoalo, Asavela Olona Kama, Andile Mtshali, Stanley Nzuzo Magini, Nikkishia Singh, et al. 2024. “Performance of Softcup® Menstrual Cup and Vulvovaginal Swab Samples for Detection and Quantification of Genital Cytokines.” Journal of Immunological Methods 528 (May): 113656. https://doi.org/10.1016/j.jim.2024.113656.\n\n\nQulu, Wenkosi Perez, Gugulethu Mzobe, Andile Mtshali, Marothi Peter Letsoalo, Farzana Osman, James Emmanuel San, Asavela Olona Kama, et al. 2023. “Metronidazole Treatment Failure and Persistent BV Lead to Increased Frequencies of Activated T- and Dendritic-Cell Subsets.” Microorganisms 11 (11): 2643. https://doi.org/10.3390/microorganisms11112643.\n\n\nSetlhare, Boitumelo, Marothi Letsoalo, Siphathimandla Authority Nkabinde, Magugu Nkabinde, Gugulethu Mzobe, Andile Mtshali, Sobia Parveen, et al. 2024. “Corrigendum: An in Vitro Study to Elucidate the Effects of Product Nkabinde on Immune Response in Peripheral Blood Mononuclear Cells of Healthy Donors.” Frontiers in Pharmacology 15 (April). https://doi.org/10.3389/fphar.2024.1401376."
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Bio3SIDS",
    "section": "",
    "text": "Welcome to Bio3SIDS — Your Experts in Biostatistics, Bioinformatics, and Bio-Data Science.\nOur dedicated team leverages the profound capabilities of data to catalyze pivotal discoveries across the biological sciences.\n\n\n\n\nWelcome to the Bio3SIDS at DATAAID Consultants\n\n\nInnovative Data Science for Global Health Challenges\nBio3SIDS Department leverages cutting-edge statistical methods to empower studies. Our data-driven insights help shape strategies that combat some of the most urgent public health issues.\nExplore Our Core Services\n\nStudy Design: Crafting the blueprint for rigorous research.\nData Management: Ensuring the integrity and security of vital research data.\nStatistical Analysis: Transforming raw data into actionable insights.\nResults Dissemination: Communicating findings to inform public health policies.\n\nEngage with Us\n\nLearn More about our impact on public health.\nCollaborate with our experts on your next project.\nJoin Our Team and make a difference.\n\nStay Updated - Subscribe to our newsletter for the latest updates and breakthroughs.\nContact Us - biosids@dataaidconsultanting.com\n\n\nOur Team is Involved every step of the way"
  }
]